Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2017 April;65(2) > Minerva Cardioangiologica 2017 April;65(2):173-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

 

REVIEW   

Minerva Cardioangiologica 2017 April;65(2):173-8

DOI: 10.23736/S0026-4725.16.04266-3

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Current aspects of pulmonary arterial hypertension and therapeutics

Xianchi LI, Yuanyuang LIU, Peiying ZHANG

Xuzhou Central Hospital, Xuzhou, China


PDF


The pulmonary arterial hypertension (PAH) patients have high rate of mortality due to right ventricle (or ventricular) (RV) failures. A lot of research work is being carried out in the area, however no treatment is available that could contrast the rise in mortality rates in PAH patients. β1-adrenoceptor blockers (β-blockers, BB) reduced mortality in left heart failure, but they do not explored much at clinical level. Recent studies suggest β-blockers might be beneficial in PAH; however the mechanisms remain unknown. The present review article would put light on all these aspects of PAH along with latest ways for the management of PAH.


KEY WORDS: Hypertension, pulmonary - Therapeutics - Adrenergic beta-antagonists

top of page